Features

Biologics, Proteins, Vaccines

CEO Spotlight: Gaston Salinas, Botanical Solution Inc.

QS-21 has become the ‘Gold Standard’ for human vaccine adjuvants and BSI is positioned to become a reliable supplier to the pharmaceutical market.

Tim Wright, Editor, Contract Pharma 09.14.21

APIs | Drug Development

API Development Trends

Why is it important to consider solid form in API development?

John Mykytiuk, Jamie Marshall and Andrew Blythe-Dickens, Sterling Pharma Solutions 09.09.21

Analytical Services | Laboratory Testing

Raman Spectroscopy for Pharmaceutical Analysis & Quality Control

Raman spectroscopy helps ensure quality along the pharma supply chain of materials—from incoming raw materials through to finished product.

Jacques Ledru, Head of Characterization, Catalent, Nottingham 09.09.21

APIs | Solid Dosage/Creams/Ointments

Spray Drying: A Proven Approach to Enhance the Solubility of APIs

Spray drying is an established particle engineering technology that offers several advantages over other methods used for improving API bioavailability.

Benzion Dolitzky, PhD, VP R&D, Wavelength Pharmaceuticals 09.09.21

APIs | Clinical Trial Materials

Outsourcing the Manufacture of Clinical Trial APIs

What to consider when deciding to partner with a CDMO for manufacturing.

Josh Hoerner, General Manager, Purisys 09.09.21

Drug Delivery

Inhaled Drug Delivery Trends

Designing dry powder devices for inhaled drugs.

Andreas M. Meliniotis, Director of Device Development, Vectura 09.09.21

A Strong Partnership in Drug Development

How CDMOs and consultants mutually benefit their clients.

Wendy Lin, Lizzie Leininger, PhD and Lizzie Leininger, PhD 09.09.21

Clinical Trial Materials | Clinical Trials | Supply Chain

Clinical Trial Kitting

Overcome the challenges to make every sample count.

Claudia Berrón and Arbi Harootoonian, Avantor 09.09.21

Logistics | Supply Chain

Maintaining Critical Drug Supply During COVID-19

Vincent Colicchio from Dr. Reddy’s talks about the challenges and solutions of maintaining supply during the pandemic.

Tim Wright, Editor, Contract Pharma 09.09.21

Drug Development

Partnering with a CDMO for Orphan Drug Development

Challenges and considerations for advancing rare disease drugs to market.

Susan Billings, Vice President & Global Head of Business Development, Curia (formerly known as AMRI) 09.09.21

Analytical Services | Bioanalytical Services

Putting Laboratory Suppliers to the Test in the COVID Era – and Beyond

Build resiliency into analytical methods through careful consideration of chromatography partners.

Hazel Dickson, PhD, Marketing Manager, Chemistry Group, Waters Corporation 09.09.21

Choosing and Managing a CDMO

Speed up your time-to-market, keep development costs under control and smooth the FDA approval and commercial launch process.

Dana Toops, President, Avema Pharma Solutions 09.09.21

Global Outsourcing Trends

Lonza’s Jan Vertommen talks about building global manufacturing and development networks to advance innovative, life-saving therapies.

Tim Wright, Editor, Contract Pharma 09.09.21

Biologics, Proteins, Vaccines | Drug Development

The Need for Standards in Cell and Gene Therapy

Identifying and understanding the areas with the greatest need for standardization to help the cell and gene industry progress.

Robert Shaw, Executive Director, Standards Coordinating Body for Regenerative Medicine 06.07.21

APIs | Drug Development

Biocatalysis: An Indispensable Tool for API Synthesis

Biocatalytic processing offers a wealth of advantages and should be evaluated during early-stage drug development.

Benzion Dolitzky, VP R&D, Wavelength Pharmaceuticals 06.07.21

Aseptic Processing | Facilities | Fill/Finish

CEO Spotlight: Patrick Haffey, Selkirk

The chief executive talks about entering the fill/finish space as a CMO startup and the company’s new aseptic fill/finish facility.

Tim Wright, Editor, Contract Pharma 06.07.21

Clinical Trial Materials | Drug Development | Preclinical Outsourcing

Strategies for Entering Phase 1 Clinical Development with Limited API

Removing API supply as a criterion in the “Go/No-Go” decision tree and enhancing the opportunity to successfully navigate the pharmaceutical “Valley of Death.”

Thomas Daggs and Angelo Consalvo, Enteris BioPharma 06.07.21

Drug Development | Preclinical Outsourcing